High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer

Qi,Xiao-Wei; Zhang,Fan; Yang,Xin-Hua; Fan,Lin-Jun; Zhang,Yi; Liang,Yan; Ren,Lin; Zhong,Ling; Chen,Qing-Qiu; Zhang,Kong-Yong; Zang,Wei-Dong; Wang,Li-Shan; Zhang,Ying; Jiang,Jun

doi:10.3892/or.2012.1906

High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer

Authors:
- Xiao-Wei Qi
- Fan Zhang
- Xin-Hua Yang
- Lin-Jun Fan
- Yi Zhang
- Yan Liang
- Lin Ren
- Ling Zhong
- Qing-Qiu Chen
- Kong-Yong Zhang
- Wei-Dong Zang
- Li-Shan Wang
- Ying Zhang
- Jun Jiang
View Affiliations

Affiliations: Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China, College of Life Sciences and Biotechnology, Shanghai Jiaotong University, Shanghai, P.R. China, City College of San Francisco, San Francisco, CA, USA
Published online on: July 12, 2012 https://doi.org/10.3892/or.2012.1906
Pages: 1231-1236

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of Wilms' tumor 1 (WT1) in breast cancer and the relationship between WT1 expression and clinicopathological factors, molecular subtypes and prognosis of breast cancer patients have not been clarified to date. We used publicly available microarray datasets of 266 early breast cancer patients to perform bioinformatics analysis on the relationship between WT1 mRNA expression and breast cancer. Results showed that WT1 mRNA expression was correlated with higher histological grades, ER-negative and basal-like and ERBB2 molecular subtypes in breast cancer. With regard to disease-free survival analysis, the WT1 high expression group showed worse prognosis than the low expression group in univariate analysis, and WT1 was demonstrated to be an independent prognostic indicator in multivariate analysis. This study confirms an oncogenic role of WT1 and demonstrates a possible relation between WT1 and progression of breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, et al: KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol. 11:1297–1304. 2009. View Article : Google Scholar : PubMed/NCBI
4	Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, et al: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell. 61:1257–1269. 1990.PubMed/NCBI
5	Little M and Wells C: A clinical overview of WT1 gene mutations. Hum Mutat. 9:209–225. 1997. View Article : Google Scholar : PubMed/NCBI
6	Loeb DM and Sukumar S: The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol. 76:117–126. 2002. View Article : Google Scholar : PubMed/NCBI
7	Hohenstein P and Hastie ND: The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet. 15:R196–R201. 2006.PubMed/NCBI
8	Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia. 21:868–876. 2007.PubMed/NCBI
9	Sugiyama H: WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 40:377–387. 2010.
10	Huff V: Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 11:111–121. 2011.
11	Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al: Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 90:194–204. 1999.
12	Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr and Daniel CW: Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA. 94:8132–8137. 1997. View Article : Google Scholar : PubMed/NCBI
13	Zhang TF, Yu SQ, Guan LS and Wang ZY: Inhibition of breast cancer cell growth by the Wilms’ tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res. 23:3575–3584. 2003.
14	Reizner N, Maor S, Sarfstein R, Abramovitch S, Welshons WV, Curran EM, et al: The WT1 Wilms’ tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol. 35:135–144. 2005.
15	Wang L and Wang ZY: The Wilms’ tumor suppressor WT1 inhibits malignant progression of neoplastigenic mammary epithelial cells. Anticancer Res. 28:2155–2160. 2008.
16	Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, et al: Absence of mutations in the Wilms’ tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol. 34:74–77. 2004.
17	Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al: Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61:921–925. 2001.
18	Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al: High expression of Wilms’ tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res. 8:1167–1171. 2002.
19	Zapata-Benavides P, Tuna M, Lopez-Berestein G and Tari AM: Downregulation of Wilms’ tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun. 295:784–790. 2002.
20	Tuna M, Chavez-Reyes A and Tari AM: HER2/neu increases the expression of Wilms’ Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 24:1648–1652. 2005.
21	Caldon CE, Lee CS, Sutherland RL and Musgrove EA: Wilms’ tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene. 27:126–138. 2008.
22	Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J and Minden MD: Wilms’ tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Mol Cancer Res. 6:1347–1355. 2008.
23	Camcı C, Kalender ME, Paydaş S, Sevinç A, Zorludemir S and Suner A: Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer. Gaziantep Med J. 17:67–72. 2011.
24	Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, et al: A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 126:407–420. 2011. View Article : Google Scholar : PubMed/NCBI
25	Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, et al: Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 68:767–776. 2008. View Article : Google Scholar : PubMed/NCBI
26	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar
27	Nie H, Neerincx PB, van der Poel J, Ferrari F, Bicciato S, Leunissen JA, et al: Microarray data mining using Bioconductor packages. BMC Proc. 3:S92009. View Article : Google Scholar : PubMed/NCBI
28	Crawford JR and Garthwaite PH: Single-case research in neuropsychology: A comparison of five forms of t-test for comparing a case to controls. Cortex. Jul 23–2011.(Epub ahead of print).
29	Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
30	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
31	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
32	Stoll R, Lee BM, Debler EW, Laity JH, Wilson IA, Dyson HJ, et al: Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol. 372:1227–1245. 2007. View Article : Google Scholar : PubMed/NCBI
33	Martínez-Estrada OM, Lettice LA, Essafi A, Guadix JA, Slight J, Velecela V, et al: Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet. 42:89–93. 2010.PubMed/NCBI
34	Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, et al: Wilms’ tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer. 44:600–608. 2008.
35	Perugorria MJ, Castillo J, Latasa MU, Goni S, Segura V, Sangro B, et al: Wilms’ tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res. 69:1358–1367. 2009.
36	Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, et al: Wilms’ tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol. 32:701–711. 2008.
37	McCarty G, Awad O and Loeb DM: WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem. 286:43634–43643. 2011. View Article : Google Scholar : PubMed/NCBI
38	Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, et al: Wilms’ tumor gene WT1 17AA(−)/KTS(−) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci. 97:259–270. 2006.